Catherine A. Foss

Imaging bacterial infections with radiolabeled 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodouracil.

Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer.

Glutamate carboxypeptidase II levels in rodent brain using [125I]DCIT quantitative autoradiography.

Synthesis of 6'-O-lissamine-rhodamine B-glucosamine as a novel probe for fluorescence imaging of lysosomes in breast tumors.

Pharmacologic and toxicologic evaluation of C. novyi-NT spores.

Synthesis and biodistribution of (11)C-GW7845, a positron-emitting agonist for peroxisome proliferator-activated receptor-{gamma}.

Virus-associated tumor imaging by induction of viral gene expression.

Radiolabeled anti-claudin 4 and anti-prostate stem cell antigen: initial imaging in experimental models of pancreatic cancer.

Imaging of musculoskeletal bacterial infections by [124I]FIAU-PET/CT.

Dysregulation of glutamate carboxypeptidase II in psychiatric disease.

N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer.

Spatio-temporal modification of collagen scaffolds mediated by triple helical propensity.

Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA).

Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors.

Imaging virus-associated cancer.

Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer.

Serial imaging of human embryonic stem-cell engraftment and teratoma formation in live mouse models.

Novel antisense oligonucleotides containing hydroxamate linkages: targeted iron-triggered chemical nucleases.

EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.

Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.

A robust approach to enhance tumor-selective accumulation of nanoparticles.

Effects of recombinant human thyroid-stimulating hormone superagonists on thyroidal uptake of 18F-fluorodeoxyglucose and radioiodide.

Sequential SPECT and optical imaging of experimental models of prostate cancer with a dual modality inhibitor of the prostate-specific membrane antigen.

2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.

Targeting collagen strands by photo-triggered triple-helix hybridization.

Dendritic cell CNS recruitment correlates with disease severity in EAE via CCL2 chemotaxis at the blood-brain barrier through paracellular transmigration and ERK activation.

Subcortical dopaminergic deficits in a DISC1 mutant model: a study in direct reference to human molecular brain imaging.

Molecular imaging of conscious, unrestrained mice with AwakeSPECT.

PET imaging in prostate cancer: focus on prostate-specific membrane antigen.

Radiochemical synthesis and in vivo evaluation of [18F]AZ11637326: an agonist probe for the α7 nicotinic acetylcholine receptor.

Effect of chelators on the pharmacokinetics of (99m)Tc-labeled imaging agents for the prostate-specific membrane antigen (PSMA).

Noninvasive molecular imaging of tuberculosis-associated inflammation with radioiodinated DPA-713.